No Data
Sansei Kokuken: Sansei Kokuken: 2024 Annual Results Forecast
Sansei Kokuken: 2024 Annual Results Forecast
Sunshine Guojian Pharmaceutical (688336.SH) has announced an expected increase, with a projected net income of 0.7 billion yuan to 0.772 billion yuan, representing a year-on-year increase of 137.73% to 162%.
Sunshine Guojian Pharmaceutical (688336.SH) released its annual performance forecast for 2024, expecting to achieve...
Sunshine Guojian Pharmaceutical Gets China Clinical Trial Nod for Autoimmune Condition Injection
The clinical trial application for the anti-TL1A monoclonal antibody SSGJ-627 independently developed by Sunshine Guojian Pharmaceutical has been accepted.
Shanghai, January 9, 2025 /PR Newswire/ -- Recently, Sunshine Guojian Pharmaceutical (688336.SH) independently developed anti-TL1A monoclonal antibody (development code: SSGJ-627) clinical trial application has been accepted by the National Pharmaceutical Administration, becoming the first domestically produced anti-TL1A monoclonal antibody to apply for and receive approval for clinical trials. TL1A (TNF ligand-related molecule 1A) is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells. It binds to DR3 (death receptor 3) to provide stimulation signals for downstream signaling pathways, regulating the proliferation, activation, apoptosis, and cellular indicators of effector cells.
Sunshine Guojian Pharmaceutical (688336.SH): The SSGJ-627 injection has received the acceptance notification for the drug clinical trial application.
On January 9, Gelonghui announced that Sunshine Guojian Pharmaceutical (688336.SH) has received the "Acceptance Notification" issued by the National Medical Products Administration, and the clinical trial application for SSGJ-627 injection (project code "SSGJ-627") has been accepted. SSGJ-627 injection is an innovative research and development product by Sunshine Guojian Pharmaceutical, possessing independent intellectual property rights for recombinant anti-TL1A humanized monoclonal antibody. TL1A (TNF ligand-related molecule 1A) is a member of the tumor necrosis factor superfamily, primarily expressed by endothelial cells. It binds to DR3 (death receptor 3) to provide downstream signaling pathways.
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) 29% Share Price Gain Is Not Telling You
